Company U.S. Stem Cell, Inc. Other OTC
Equities
USRM
US90350U1007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Autologous Cell Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 17-03-04 |
Director/Board Member | 100 | 03-05-31 | |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Sheldon Anderson
BRD | Director/Board Member | 73 | 13-08-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 641,507,317 | 571,247,298 ( 89.05 %) | 0 | 89.05 % |
Company contact information
U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway 4th floor
33323-6217, Sunrise
+954 835 1500
http://www.us-stemcell.comSector
1st Jan change | Capi. | |
---|---|---|
+3.61% | 106B | |
+7.02% | 23.47B | |
-14.80% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.29% | 16.78B | |
+5.25% | 14.41B | |
+36.49% | 12.86B | |
+327.57% | 8.78B |